PortfoliosLab logoPortfoliosLab logo
ABBV vs. GRC
Performance
Return for Risk
Drawdowns
Volatility
Dividends
Financials

Performance

ABBV vs. GRC - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in AbbVie Inc. (ABBV) and The Gorman-Rupp Company (GRC). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period

In the year-to-date period, ABBV achieves a 12.42% return, which is significantly lower than GRC's 70.94% return. Over the past 10 years, ABBV has outperformed GRC with an annualized return of 18.94%, while GRC has yielded a comparatively lower 14.38% annualized return.


ABBV

1D
-2.51%
1M
0.66%
6M
14.27%
YTD
12.42%
1Y
36.88%
3Y*
23.28%
5Y*
20.99%
10Y*
18.94%
ALL TIME*
20.35%

GRC

1D
0.62%
1M
-8.49%
6M
49.80%
YTD
70.94%
1Y
100.02%
3Y*
38.18%
5Y*
20.22%
10Y*
14.38%
ALL TIME*
11.19%
*Multi-year figures are annualized to reflect compound growth (CAGR)

Liquidity Comparison


PositionAvg. Volume Value (2W)Avg. Volume Value (1M)Avg. Volume Value (3M)
$1.40B$1.53B$1.60B
$19.01M$17.85M$14.41M

ABBV vs. GRC - Yearly Performance Comparison


2026 (YTD)202520242023202220212020201920182017
ABBV
AbbVie Inc.
12.42%33.08%18.86%-0.23%24.01%32.43%27.72%1.47%-0.96%60.07%
GRC
The Gorman-Rupp Company
70.94%28.24%8.87%42.15%-41.17%39.71%-11.90%17.64%11.75%2.49%

Correlation

The correlation between ABBV and GRC is 0.12, which is low. Their historical price movements had little consistent relationship.


Correlation
Correlation (1Y)
Focuses on recent behavior, but can change the most.

0.12

Correlation (3Y)
Balances recent behavior with more history.

0.15

Correlation (5Y)
Shows whether the relationship held over a longer period.

0.16

Correlation (10Y)
Provides a long-term view across more market conditions.

0.22

Correlation (All Time)
Calculated using the full available price history since Jan 2, 2013

0.25

The correlation between ABBV and GRC shifts across timeframes, from 0.12 (1 year) to 0.25 (all time), reflecting how their relationship changes across market environments.

Fundamentals

Market Cap

ABBV:

$443.24B

GRC:

$2.14B

EPS

ABBV:

$2.05

GRC:

$2.37

PE Ratio

ABBV:

122.29

GRC:

34.27

PS Ratio

ABBV:

7.08

GRC:

3.04

PB Ratio

ABBV:

16.19

GRC:

4.85

Total Revenue (TTM)

ABBV:

$62.82B

GRC:

$702.05M

Gross Profit (TTM)

ABBV:

$46.15B

GRC:

$214.56M

EBITDA (TTM)

ABBV:

$17.96B

GRC:

$129.99M

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

ABBV vs. GRC — Risk / Return Rank

Compare historical risk-adjusted metric ranks over the past 12 months.

ABBV
ABBV Risk / Return Rank: 8181
Overall Rank
ABBV Sharpe Ratio Rank: 8484
Sharpe Ratio Rank
ABBV Sortino Ratio Rank: 8282
Sortino Ratio Rank
ABBV Omega Ratio Rank: 8080
Omega Ratio Rank
ABBV Calmar Ratio Rank: 8080
Calmar Ratio Rank
ABBV Martin Ratio Rank: 7979
Martin Ratio Rank

GRC
GRC Risk / Return Rank: 9696
Overall Rank
GRC Sharpe Ratio Rank: 9797
Sharpe Ratio Rank
GRC Sortino Ratio Rank: 9696
Sortino Ratio Rank
GRC Omega Ratio Rank: 9494
Omega Ratio Rank
GRC Calmar Ratio Rank: 9797
Calmar Ratio Rank
GRC Martin Ratio Rank: 9797
Martin Ratio Rank
The rank (0–100) uses a weighted average of the Sharpe, Sortino, Omega, Calmar, and Martin percentile ranks for the trailing 12 months. Higher means stronger historical risk-adjusted performance within the peer group.

ABBV vs. GRC - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for AbbVie Inc. (ABBV) and The Gorman-Rupp Company (GRC). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.


ABBVGRCDifference
Sharpe ratioReturn per unit of total volatility

-1.39

Sortino ratioReturn per unit of downside risk

-1.57

Omega ratioGain probability vs. loss probability

1.26

1.44

-0.18

Calmar ratioReturn relative to maximum drawdown

2.14

6.75

-4.61

Martin ratioReturn relative to average drawdown

4.73

17.21

-12.48

ABBV vs. GRC - Sharpe Ratio Comparison

The current ABBV Sharpe Ratio is 1.42, which is lower than the GRC Sharpe Ratio of 2.81. The chart below compares the historical Sharpe Ratios of ABBV and GRC, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.


Loading charts...

Drawdowns

ABBV vs. GRC - Drawdown Comparison

The maximum ABBV drawdown since its inception was -45.09%, smaller than the maximum GRC drawdown of -67.23%. Use the drawdown chart below to compare losses from any high point for ABBV and GRC.


Loading charts...

Drawdown Indicators


ABBVGRCDifference

Max Drawdown

Largest peak-to-trough decline

-45.09%

-67.23%

+22.14%

Max Drawdown (1Y)

Largest decline over 1 year

-17.32%

-14.90%

-2.42%

Max Drawdown (3Y)

Largest decline over 3 years

-20.74%

-26.87%

+6.13%

Max Drawdown (5Y)

Largest decline over 5 years

-21.92%

-49.26%

+27.34%

Max Drawdown (10Y)

Largest decline over 10 years

-45.09%

-49.26%

+4.17%

Current Drawdown

Current decline from peak

-4.69%

-11.50%

+6.81%

Average Drawdown

Average peak-to-trough decline

-10.64%

-17.59%

+6.95%

Ulcer Index

Depth and duration of drawdowns from previous peaks

7.81%

5.83%

+1.98%

Volatility

ABBV vs. GRC - Volatility Comparison

The current volatility for AbbVie Inc. (ABBV) is 8.35%, while The Gorman-Rupp Company (GRC) has a volatility of 12.13%. This indicates that ABBV experiences smaller price fluctuations and is considered to be less risky than GRC based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading charts...

Volatility by Period


ABBVGRCDifference

Volatility (1M)

Calculated over the trailing 1-month period

8.35%

12.13%

-3.78%

Volatility (6M)

Calculated over the trailing 6-month period

19.56%

30.07%

-10.51%

Volatility (1Y)

Calculated over the trailing 1-year period

26.14%

35.80%

-9.66%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

23.46%

31.19%

-7.73%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

25.92%

34.00%

-8.08%

Dividends

ABBV vs. GRC - Dividend Comparison

ABBV's dividend yield for the trailing twelve months is around 2.72%, more than GRC's 0.93% yield.


PositionTTM20252024202320222021202020192018201720162015
ABBV
AbbVie Inc.
2.72%2.87%3.49%3.82%3.49%3.84%4.41%4.83%3.89%2.65%3.64%3.41%
GRC
The Gorman-Rupp Company
0.93%1.56%1.91%1.98%2.67%1.43%1.82%1.47%7.74%1.51%1.39%1.52%

Financials

ABBV vs. GRC - Financials Comparison

This section allows you to compare key financial metrics between AbbVie Inc. and The Gorman-Rupp Company. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


Values in USD except per share items

ABBV vs. GRC - Profitability Comparison

The chart below illustrates the profitability comparison between AbbVie Inc. and The Gorman-Rupp Company over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

Gross Margin
Operating Margin
Net Margin
Quarterly
Annual

ABBV - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Aug 2026, AbbVie Inc. reported a gross profit of 12.53B and revenue of 15.00B. Therefore, the gross margin over that period was 83.5%.

GRC - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Aug 2026, The Gorman-Rupp Company reported a gross profit of 63.69M and revenue of 186.07M. Therefore, the gross margin over that period was 34.2%.

ABBV - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Aug 2026, AbbVie Inc. reported an operating income of 4.73B and revenue of 15.00B, resulting in an operating margin of 31.6%.

GRC - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Aug 2026, The Gorman-Rupp Company reported an operating income of 30.41M and revenue of 186.07M, resulting in an operating margin of 16.3%.

ABBV - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Aug 2026, AbbVie Inc. reported a net income of 699.00M and revenue of 15.00B, resulting in a net margin of 4.7%.

GRC - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Aug 2026, The Gorman-Rupp Company reported a net income of 19.43M and revenue of 186.07M, resulting in a net margin of 10.4%.


Frequently Asked Questions


ABBV and GRC have a correlation of 0.12, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

GRC has higher volatility (12.13%) compared to ABBV (8.35%). In terms of maximum drawdown, ABBV dropped -45.09% vs GRC's -67.23%.

GRC currently has the higher Sharpe Ratio (2.81 vs 1.42), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.

Portfolio Optimizer

Find the right allocation for ABBV and GRC

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer